Search research articles
Contact Us
Filters
Showing results (181-190 of 196) with videos related to
Page
of 20
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
D Y C Heng, T K Choueiri, B I Rini, et al.
Nature Biotechnology
|
September 7, 2021
Integration of spatial and single-cell transcriptomic data elucidates mouse organogenesis
T Lohoff, S Ghazanfar, A Missarova, et al.
BMC Cancer
|
May 25, 2021
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Current Oncology (Toronto, Ont.)
|
May 3, 2019
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
I Stukalin, J C Wells, J Graham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
D E Rathkopf, M R Patel, A D Choudhury, et al.
British Journal of Cancer
|
April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
J J Ko, T K Choueiri, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88]
D E Rathkopf, M R Patel, A D Choudhury, et al.
World Journal of Cardiology
|
October 2, 2010
Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction
Vinod Jorapur, Gervasio A Lamas, Zygmunt P Sadowski, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 196) with videos related to
Sort By:
Page
of 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
D Y C Heng, T K Choueiri, B I Rini, et al.
Nature Biotechnology
|
September 7, 2021
Integration of spatial and single-cell transcriptomic data elucidates mouse organogenesis
T Lohoff, S Ghazanfar, A Missarova, et al.
BMC Cancer
|
May 25, 2021
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Current Oncology (Toronto, Ont.)
|
May 3, 2019
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
I Stukalin, J C Wells, J Graham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
D E Rathkopf, M R Patel, A D Choudhury, et al.
British Journal of Cancer
|
April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
J J Ko, T K Choueiri, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88]
D E Rathkopf, M R Patel, A D Choudhury, et al.
World Journal of Cardiology
|
October 2, 2010
Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction
Vinod Jorapur, Gervasio A Lamas, Zygmunt P Sadowski, et al.
Page
of 20